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Objective Review of Mediastinal Lymph Node Examination
in a Lung Cancer Resection Cohort
Raymond U. Osarogiagbon, MBBS, FACP,* Jeffrey W. Allen, MD,* Aamer Farooq, MD,†
and James T. Wu, MD‡
Background: Accurate staging of resected lung cancer requires
mediastinal lymph node (MLN) examination. MLN dissection
(MLND) and systematic sampling (SS) are acceptable procedures;
random sampling (RS) and no sampling (NS) are not. Forty percent
of US lung cancer resections have NS. We closely examined the
pattern of MLN examination in a lung resection cohort.
Methods: This is a retrospective review of all lung cancer resections
in Memphis, TN, from 2004 to 2007. We compared operating
surgeons’ claims to the pathology report and an audit of the oper-
ation narrative by an independent surgeon.
Results: Forty-five percent of resections were reported by surgeons
as MLND, 8% RS, and 48% NS. None met pathology criteria for
MLND, 9% were SS, 50% were RS, and 42% were NS. The
concordance rate between the operating surgeon and pathology
report was 39%. The surgeon audit suggested 29% of resections had
MLND, 26% RS, and 45% NS. Concordance between operating and
auditing surgeons was 71%. Sublobar resection, T1 stage, and age
were associated with NS.
Conclusions: Most resections had suboptimal MLN examination.
Concordance was poor between surgeon claims, objective review
of pathology reports, and an independent surgeon audit. The
higher concordance between operating and auditing surgeons
may suggest incomplete pathology examination of MLN mate-
rial. The terms used by operating surgeons to describe MLN
retrieval were often inaccurate.
Key Words: Cancer, Lymph nodes, Lung cancer surgery, Medias-
tinal lymph nodes, Pathology dissection.
(J Thorac Oncol. 2012;7: 390–396)
The status of the mediastinal lymph nodes (MLN) is themost important prognostic factor after surgical resection
of early stage non-small cell lung cancer (NSCLC).1 Nonop-
erative methods of evaluating MLN have limitations in sen-
sitivity, specificity, and thoroughness of application.2,3 His-
tologic examination of lymph nodes within the surgical
resection specimen is the most accurate means of determining
lymph node involvement. Patients with MLN involvement
benefit from postoperative adjuvant chemotherapy and radi-
ation therapy. Because the benefit is modest, there remains
interest in clinical trials of new adjuvant treatments that might
improve on current results. Enrollment of homogenous
groups of patients into such clinical trials may be impaired by
poor lymph node staging.
The optimal surgical lymph node examination proce-
dure remains controversial. While some at one extreme ad-
vocate en bloc complete MLN dissection (MLND) on all
patients,4 at the other end of the opinion spectrum, others
advocate eliminating MLN sampling for certain apparently
low-risk patients such as those with small, peripheral lesions,
and no frozen section evidence of hilar or peribronchial
lymph node involvement.5 However, patients who undergo
nonsystematic MLN sampling have inferior survival,6 and
most practice guidelines advocate a systematic approach to
MLN staging.7,8
Analyses of national databases show significant vari-
ability in MLN examination practice and low lymph node
retrieval rates.9,10 Theoretical concerns about the safety of
routine MLND have not been validated in clinical trials.11
More extensive staging procedures have the putative advan-
tage of assuring true pathologic lymph node stage, potentially
enabling more accurate recommendations for postoperative
management.
The multiplicity of terms used to describe surgical
collection of the MLN specimen introduces an element of
confusion about the specifics of the actual reference surgical
procedure. To address this problem, the International Asso-
ciation for the Study of Lung Cancer introduced the term
“systematic nodal dissection” in an effort to achieve consen-
sus in nomenclature and to define minimum standards.12
Nevertheless, it is often still not clear precisely what is meant
by the terms used to report intraoperative MLN collection for
examination by a pathologist.
We attempted to objectively evaluate the pattern of
MLN examination during surgery for NSCLC in our com-
munity. We used predefined objective criteria to identify the
actual procedures done, compared these with the surgeons’
reported lymph node examination procedures, and evaluated
the extent to which practice met specific standards.
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PATIENTS AND METHODS
The Memphis Metropolitan Area Quality of Surgical
Resection (MMA-QSR) cohort is a serially updated database
of all patients who underwent surgical resection for lung
cancer in the MMA. Construction and analysis of the dataset
were approved by the Institutional Review Boards of the
University of Tennessee and all institutions contributing data,
which also waived the informed consent requirement. The
current report includes operations performed from January 1,
2004, to December 30, 2007. We excluded patients who
received preoperative chemotherapy or radiation therapy or
both. As we have described elsewhere, this cohort has similar
characteristics to datasets from the Surveillance, Epidemiol-
ogy, and End Results (SEER) program and the National
Cancer Data Base (NCDB) and probably reflects the general
practice of lung cancer surgery in the United States.13,14
Objective Definition of MLN Examination
Procedure
We used predefined criteria to classify the operative
lymph node staging procedure by what was found in the
pathology report. We defined MLND according to the Amer-
ican College of Surgeons Oncology Group (ACOSOG)
Z0030 criteria, which required examination of lymph nodes
from the American Thoracic Society stations 2R, 4R, 7, 8,
and 9 for right-sided tumors and 4L, 5, 6, 7, 8, and 9 for
left-sided tumors.11 We defined systematic sampling (SS)
with a hierarchy of stringency, which required at least one
lymph node from stations 2R, 4R, 7, and 10R for right-sided
tumors and 5, 6, 7, and 10L for left-sided tumors (ACOSOG
criteria)11; or 4R, 7, and 9 for right- and 5, 6, 7, and 9 for
left-sided tumors (OSI Pharmaceutical’s RADIANT trial def-
inition)15; or 4R and 7 for right- and 5, 6, and 7 for left-sided
tumors (Eastern Cooperative Oncology Group 1505 study
definition).16 Any one of these criteria was accepted as SS.
We classified resections which failed to meet criteria for
MLND or SS, but in which at least one MLN was present in
the pathology specimen, as random sampling (RS). Finally,
resections in which no MLN were present were classified as
no sampling (NS).
In addition, we performed a secondary analysis in
which we defined MLND with less stringent criteria, to
account for possible lumping together of lymph node speci-
mens from anatomically proximate stations. In this analysis,
MLND in right-sided resections had to have at least one
lymph node from 2R or 4R, 7, 8, or 9, and 10R; left-sided
resections had to include 4L or 5 or 6, 7, 8 or 9, and 10L.
Lymph nodes obtained by preresection surgical mediastinal
staging methods such as mediastinoscopy and mediastinot-
omy were included in the pathologic lymph node counts. All
references to lymph node stations are to the American Tho-
racic Society lymph node map, which was in use during the
time span of our study.
The operating surgeon’s self-identified MLN collection
procedure was obtained from the title of the operation notes.
We obtained each surgeon’s board certification status and
practice information from the Cardiothoracic Surgery Net-
work (http://www.ctsnet.org) and cross-checked with the Amer-
ican Board of Medical Specialties (http://www.abms.org).
Independent Surgical Audit
The full text of all operation notes, with patient, sur-
geon, institutional, and other identifiers redacted, were au-
dited by an experienced board-certified cardiothoracic sur-
geon at a high-volume academic cancer institution in a
different city. The auditing surgeon, blinded to the pathology
report, provided an interpretation of the procedure described
in the narrative of the operation note, classifying all lymph
node collection procedures into one of the four groups de-
fined above.
Statistical Methods
The summary data were mostly descriptive. We used
the 2 test or Fisher’s exact test to compare the characteristics
of patients classified on the basis of the pathology report into
the different lymph node dissection cohorts.
RESULTS
There were 806 resections in the whole cohort, from
which we eliminated 58 resections that were preceded by
chemotherapy and/or radiation therapy. Sixteen of the eligi-
ble 748 reports did not make it to the external auditor, leaving
an examination cohort of 732 resections, which represents
98% of the eligible cohort. The median age of this examination
cohort was 68 years (range, 37–89 years). Details of patient
demographics, disease characteristics, and type of resection are
reported in Table 1. Ninety-five percent of resections were
performed by board-certified cardiothoracic surgeons, and
5% were done by specialty trained, nonboard-certified car-
diothoracic surgeons. No resections were performed by gen-
eral surgeons.
Surgeon Claims, Independent Surgery Audit,
and Pathology Report Findings
The operating surgeon identified the lymph node col-
lection procedure as MLND in 45% of cases, RS in 8%, and
did not claim an MLN evaluation procedure in 48% (Table
2). No surgeon claimed an SS procedure. The independent
review surgeon identified the lymph node examination pro-
cedure as MLND in 29%, SS in 0.3%, RS in 26%, and NS in
45% of resections. The review of lymph nodal examination in
the pathology report suggested that no patient received a
lymph node examination procedure that met criteria for
MLND, 9% had SS, 50% had RS, and 42% had NS.
Table 3 compares the demographic, disease, and resec-
tional characteristics of patients sorted by the objective (pa-
thologist determined) lymph node dissection procedure. The
median age of the patients differed significantly among the
groups. Patients who had NS were older than those with any
form of sampling (p  0.05). Race, sex, or histology did not
differ significantly between the lymph node procedure
groups. Majority of patients had T1 and T2 disease, but there
was a higher proportion of T1 patients in the poorly sampled
groups (RS and NS) than in the SS group (p  0.01). The
extent of resection differed between the lymph node dissec-
tion groups (p  0.0001). For example, 19% of patients who
underwent pneumonectomy had no MLN, compared with
41% of those who had lobectomy/bilobectomy and 62% of
those who had sublobar resection.
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Concordance Between Operating Surgeon and
Pathology Report
There was a great degree of discordance between the
operating surgeon’s claimed lymph node dissection proce-
dure and the pathology report (Table 2). None of the 326
resections in which the operating surgeon claimed MLND
met objective criteria, 15% met criteria for SS, 68% were RS,
and 17% had no MLN. Of the 350 resections in which the
operating surgeon did not claim an MLN examination pro-
cedure, 3% met criteria for SS, 29% had RS, and 68% had no
lymph nodes. Majority of the 56 surgeon-reported RS cases
met pathology RS criteria, but 18% had no lymph nodes
(Table 2). The overall concordance between the operating
surgeon and pathologist was 39%. Most of the concordant
cases were those with no lymph nodes. With exclusion of the
350 cases in which the surgeon indicated no lymph node
procedure, the concordance rate dropped to 11%.
Concordance Between Operating and
Independent Review Surgeons
The concordance rate between surgeons was moder-
ately high (Table 2). The auditing surgeon concurred with
61% of the operating surgeons’ claims of MLND but deter-
mined that the procedure described was a lesser dissection in
24%. However, the auditor found no description of a lymph
node collection procedure in 15% of the claimed MLND
cases. At the other extreme, when the operating surgeon did
not claim a lymph node collection procedure, there was
sufficient description in the operation notes to suggest MLND
in 3%, RS in 18%, and SS in 0.3%. However, 78% had no
evidence of an MLN collection procedure. The overall con-
cordance between the operating and auditing surgeons was
71%. With elimination of the 350 cases without a claimed
lymph node collection procedure, the concordance rate be-
tween surgeons was 64%.
Concordance Between Independent Surgeon
and Pathology Report
None of the 212 cases that the independent reviewer
determined had received MLND met pathology criteria for
MLND, 22% met SS criteria, 65% met RS criteria, and 14%
had no lymph nodes (Table 4). Of the 329 cases determined
by the independent surgeon to have had NS, 70% had no
lymph nodes in the pathology report, 29% had evidence of
RS, and 1% had evidence of SS. Of the 189 cases deemed to
have received RS, 69% met pathology criteria for RS, 23%
had no lymph nodes, and 8% had evidence of SS. The overall
concordance rate between the independent reviewer and the
pathology report was 49%. With elimination of the 329 cases
TABLE 1. MMA-QSR Cohort: Patient Demographics,
Disease, and Surgical Resection Characteristics
Variable Number of Patients Percentage
Age (yr)
45 13 2
45 to 65 301 41
65 418 57
Sex
Female 353 48
Male 379 52
Race
Black 169 23
White 559 76
Other 4 0.5
Health insurance status
Commercial 226 31
Medicaid 38 5
Medicare 430 59
None 38 5
Histology
Adenocarcinoma 326 45
Squamous cell 263 36
Other 143 20
T stage
T1 373 51
T2 271 37
T3 28 4
T4 55 8
TX 5 1
Extent of surgery
Pneumonectomy 78 11
Lobectomy/bilobectomy 569 78
Sublobar resection 85 12
MMA-QSR, Memphis Metropolitan Area Quality of Surgical Resection.
TABLE 2. Independent Surgical Determination of Lymph
Node Collection Procedure Compared with Operating
Surgeon Claims and Pathology Reports
Mediastinal Lymph Node Collection Procedure
Claimed by Operating Surgeon, % (N)
MLND 45a
(N  326)
SS
(N  0)
RS 8a
(N  56)
NS 48a
(N  350)
Independent
reviewer,
% (n)
MLND, 29 (212) 61 (198) 0 (0) 4 (2) 3 (12)
SS, 0.3 (2) 0 (1) 0 (0) 0 (0) 0.3 (1)
RS, 26 (189) 24 (77) 0 (0) 86 (48) 18 (64)
NS, 45 (329) 15 (50) 0 (0) 11 (6) 78 (273)
Concordance rate
Overall 71%
Excluding NS 64%
Pathology report,
% (n)
MLND, 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
SS, 9 (64) 15 (50) 0 (0) 5 (3) 3 (11)
RS, 50 (364) 68 (221) 0 (0) 77 (43) 29 (100)
NS, 42 (304) 17 (55) 0 (0) 18 (10) 68 (239)
Concordance rate
Overall 39%
Excluding NS 11%
a Percent of whole cohort. Percentages may not add up to 100% because of
rounding.
MLND, mediastinal lymph node dissection; SS, systematic sampling; RS, random
sampling; NS, no sampling.
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deemed by the independent reviewer not to have had any
lymph node collection, the concordance rate between the
independent surgeon and the pathologist was 33%.
Secondary Analysis with Less Stringent
Pathology Criteria for MLND
Because lymph nodes may be anatomically absent in
certain stations, and also to account for the possibility that
specimens from anatomically adjacent lymph node stations
may be combined in material submitted to pathologists, we
analyzed the data using a modification of the ACOSOG
Z0030 criteria for MLND. As shown in Table 5, this had
minimal impact on the discordance in classification of MLN
collection procedure between the surgeons and the pathology
report. The number of lymph nodes examined was low across
the board (Table 6).
Comment
We found a high rate of discordance between operating
surgeons’ description of MLN collection procedure and
lymph nodes evaluated by pathologists after resection of
TABLE 4. Concordance Between Pathology Report and
Independent Surgical Audit
Mediastinal Lymph Node
Procedure Determined from
Pathology Report, % (N)
SS 9a
(N  64)
RS 50a
(N  364)
NS 42a
(N  304)
Independent surgical audit
MLND 72 (46) 38 (137) 10 (29)
SS 0 (0) 0.3 (1) 0.3 (1)
RS 23 (15) 36 (131) 14 (43)
NS 5 (3) 26 (95) 76 (231)
Concordance rate
Overall 49%
Excluding NS 33%
a Percent of whole cohort. Percentages may not add up to 100% because of
rounding.
MLND, mediastinal lymph node dissection; SS, systematic sampling; RS, random
sampling; NS, no sampling.
TABLE 3. Demographic, Disease, and Surgical Characteristics of Patients Sorted by Type of
Mediastinal Lymph Node Procedure as Determined from the Pathology Report
Objective Mediastinal Lymph Node Procedure
Determined from Pathology Report, % (N)
MLND
0 (0)
SS
9 (64)a
RS
50 (364)a
NS
42 (304)a p
Age, median (range) 67 (48–84)b 66 (39–89)b 69 (37–87)b 0.03
Sex
Female 0 (0) 53 (34) 45 (164) 51 (155) 0.22
Male 0 (0) 47 (30) 55 (200) 49 (149)
Race
Black 0 (0) 30 (19) 26 (92) 19 (58) 0.0683
White 0 (0) 70 (45) 75 (269) 81 (245)
Histology
Adenocarcinoma 0 (0) 47 (30) 46 (168) 42 (128) 0.86
Squamous 0 (0) 34 (22) 35 (128) 37 (113)
Other 0 (0) 19 (12) 19 (68) 21 (63)
T stage
T1 0 (0) 42 (27) 46 (166) 60 (180) 0.01
T2 0 (0) 47 (30) 41 (150) 30 (91)
T3 0 (0) 3 (2) 5 (18) 3 (8)
T4 0 (0) 8 (5) 8 (28) 7 (22)
Extent of surgery
Pneumonectomy 0 (0) 16 (10) 15 (53) 5 (15)
Lobe/bilobectomy 0 (0) 75 (48) 78 (285) 78 (236) 0.0001
Sublobar 0 (0) 9 (6) 7 (26) 17 (53)
Number of lymph nodes, median (range) 0.0001
All 0 8 (2–30)b 6 (1–45)b 2 (0–18)b
Mediastinal LN 0 4 (2–19)b 2 (1–29)b 0 (0–0)b
Number of lymph node stations, median (range) 0.0001
All 0 4 (2–6)b 3 (1–6)b 1 (0–3)b
Mediastinal 0 3 (2–5)b 1 (1–4)b 0 (0–0)b
a Percent of whole cohort. Percentages may not add up to 100 because of rounding.
b Median (range).
MLND, mediastinal lymph node dissection; SS, systematic sampling; RS, random sampling; NS, no sampling.
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NSCLC in our cohort. This discordance was particularly
striking with regard to MLND. None of the surgeon-ascribed
MLND cases met our predefined pathology criteria; even the
29% of cases which an independent auditor determined suf-
ficiently described an MLND procedure in the operation
notes. After we modified the definition of MLND to account
for possible clustering of specimens from anatomically adja-
cent lymph node stations, only 2% of all cases met the less
stringent objective criteria.
On the basis of the pathology findings, majority of
these procedures seemed to be better classified as RS. Even
worse, 18% had no MLN. We also found that surgeons
frequently omit any reference to MLN collection in their
operation notes (42–48% of the whole cohort). The majority
of these cases had no MLN in the pathology specimen. The
dataset shows that the overwhelming majority of lung resec-
tion procedures in this community-based cohort were subop-
timal, either RS or NS, which together constituted 92% by
pathology criteria, 70% by independent audit, and 55% by
operating surgeon reports.
There are essentially four possible sets of explanations
for our findings: the patient had no nodes to take out; the
surgeon did not take the nodes out or incorrectly documented
the procedure performed; the nodes were taken out but the
pathologist did not examine them or incorrectly identified
their stations of origin; and our study protocol misinterpreted
the clinical events. The first scenario has been reported in
cadaveric studies of MLN.17 The number of lymph nodes
varies between individuals and may reflect the interaction
between tumor and host factors.18 Because it can be modified
by prior therapy, we eliminated patients who received preop-
erative chemotherapy or radiation therapy from this analysis.
However, “host factors” seems an unlikely explanation for
the extremely low number of lymph nodes examined in the
overall cohort. For example, in the ACOSOG Z0030 trial, at
least one lymph node was examined in each of the mandated
stations, the median number of MLN examined was about 12,
and a median of at least six nodes were examined from at
least three stations in 99% of patients.19 We hypothesize that
most of the problems occur somewhere between the surgical
procedure itself, the documentation of the surgical procedure,
the communication between the surgeon and pathologist, and
the pathology examination.
Analyses of the SEER and NCDB datasets reveal that
40% of lung resections in the United States have no MLN
examined,9,10 identical to our cohort. It seems likely that
surgeon practice is a major contributor to this phenomenon.
One possibility is that some specimens turn out not to contain
lymph nodes on microscopy, which may explain the absence
of lymph nodes in 18% of instances when any type of lymph
node collection was claimed, analogous to the NCDB anal-
ysis of Little et al. in which 53% of mediastinoscopy speci-
mens had no lymph node material delivered to the patholo-
gist.10 Additional problems include poorly written operation
notes, which obscure the true extent of dissection performed.
TABLE 5. Mediastinal Lymph Node Procedure Determined
by Less Stringent Pathology Criteria Using a Modification of
ACOSOG Z0030 MLND Criteria to Account for Possible
Clustering of Specimens from Adjacent Mediastinal Lymph
Node Stations, Compared with Operating Surgeon Claims
and Independent Audit of Surgeons’ Operation Notes
MLN Procedure Determined from
Pathology Report, % (N)
MLND SS RS NS
2a
(N  15)
7a
(N  51)
49a
(N  362)
42a
(N  304)
Operating surgeon, N (%)
MLND 80 (12) 78 (40) 61 (219) 18 (55)
SS 0 (0) 0 (0) 0 (0) 0 (0)
RS 7 (1) 4 (2) 12 (43) 3 (10)
NS 13 (2) 18 (9) 28 (100) 79 (239)
Concordance rate
Overall 40%
Excluding NS 14%
Independent reviewer, N
(%)
MLND 73 (11) 73 (37) 37 (135) 10 (29)
SS 0 (0) 0 (0) 0.3 (1) 0.3 (1)
RS 20 (3) 24 (12) 36 (131) 14 (43)
NS 7 (1) 4 (2) 26 (95) 76 (231)
Concordance rate
Overall 51%
Excluding NS 35%
Number of MLN
examined
5 (3–11)b 4 (2–19)b 2 (1–29)b 0 (0–0)b
Number of MLN stations 3 (3–4)b 2 (2–5)b 1 (1–4)b 0 (0–0)b
a Percent of whole cohort. Percentages may not add up to 100% because of
rounding.
b Median (range).
MLND, mediastinal lymph node dissection; SS, systematic sampling; RS, random
sampling; NS, no sampling; ACOSOG, American College of Surgeons Oncology
Group.
TABLE 6. Comparison of Number of Lymph Nodes in Each
Category of MLN Examination Identified
Type of MLN Examination
Objective Evaluation of Quality
of MLN Examination Based on
Lymph Node Counts
Operating
Surgeon
Auditing
Surgeon
Pathology
Report
Number of MLN examined median
(interquartile range)
MLND 2 (1–4) 3 (1–5) —
SS — 2 (0–4) 4 (3–7)
RS 1 (1–2) 2 (1–3) 2 (1–4)
NS 0 (0–1) 0 (0–1) 0 (0–0)
Percentage of cases with 12 or more
MLN examined
MLND 2.5 3.8 —
SS — 0 8
RS 0 0.5 1
NS 0.6 0.3 0
MLND, mediastinal lymph node dissection; SS, systematic sampling; RS, random
sampling; NS, no sampling.
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This may explain why 33% of the cases in which the operating
surgeon did not indicate any type of lymph node dissection
actually had at least one MLN examined by the pathologist. The
terms “radical MLND,” “complete MLND,” “mediastinal
lymphadenectomy,” and “MLN sampling” seemed to be used
nonspecifically. Although these terms have been variably de-
fined in the published literature,4–7,11,12,15,16,20,21 none of these
definitions seem to have been adopted in our community.
We chose the pathology report as the most objective
determinant of what was actually performed in the operating
room, because it is the document from which almost all
postoperative oncologic care decisions will be made. How-
ever, experience with other cancers illustrates the variation in
pathologists’ ability and willingness to seek out lymph nodes
within resection specimens.22–24 Pathologists may fail to
identify, examine, or report on lymph nodes that are present
in resection specimens, especially when not specifically
isolated and labeled. For example, we have previously
reported that about 18% of patients in the MMA-QSR
cohort had no N1 lymph nodes examined by the patholo-
gist.14 Incomplete pathology examination may explain the
higher concordance rate between the surgeons (66% with
positive identification of a lymph node procedure) than
either the independent surgeon and pathologist (33%) or
operating surgeon and pathologist (11%).
A fourth possible set of explanations for our findings
relate to the limitations of a retrospective study. We may have
underestimated the extent of preoperative MLN examination.
Although we incorporated lymph nodes obtained before the
resection in our pathologic lymph node counts, procedures
such as mediastinoscopy performed at institutions not in-
cluded in our study would have been omitted. However, we
believe that, if present, this was a very infrequent occurrence.
Our definition of MLND may have been too stringent, al-
though we adjusted for this by allowing for multiple defini-
tions of SS, which can also be considered as an adequate
MLN collection procedure.5,20,25 Lessening the stringency of
the MLND criteria to account for anatomic variation in lymph
node location and numbers, and also to account for the
possibility that anatomically adjacent stations might have
been submitted together, did not much change the concor-
dance rates between the surgeon observers and the pathology
report findings (Table 5).
Other theoretical concerns, such as the possibility that
the independent auditor may have misinterpreted the opera-
tion notes, despite his experience in a high-volume cancer
center and despite our attempt to avoid bias by blinding him
to the pathology reports, and the possibility that most patients
who had NS may have had high operative risk, leading the
surgeons to prudently forgo any attempt at MLN collection,
will not adequately explain the low concordance rate between
the three different observers. The main problem seems to
stem from low lymph node examination rates across the
board (Table 6).
The MMA-QSR cohort is a community-based group,
and better results can probably be obtained at high-volume
tertiary care centers of excellence. However, the majority of
lung cancer surgery in the United States is performed in
community hospitals. The MMA-QSR cohort closely approx-
imates what is known about current practice in the United
States. Indeed, the fact that 95% of all resections in our cohort
were performed by board-certified specialty surgeons (com-
pared with 76% in the US population)26 suggests that the
MMA-QSR results might be superior to the national average.
Analyses of SEER,9 NCDB,10 and California Cancer Regis-
try27 data suggest the problems we highlight are widespread.
In summary, we have demonstrated major problems in
the reporting of MLN examination procedures in this com-
munity-based cohort of patients who underwent potentially
curative resection for lung cancer. There was widespread
inaccuracy in identification of the MLN collection procedure
performed and suboptimal lymph node sampling by objective
criteria. We can only speculate on the underlying causes of
these findings, but we are currently conducting studies to
quantify the differential contribution of operating room and
pathology laboratory practices. We plan to design corrective
interventions specific to the sites where the quality care
deficits occur.
Meanwhile, we need better training on acceptable MLN
examination procedures for surgeons and pathologists. This
training must emphasize that the debate about equivalence
between MLND and SS does not suggest any ambiguity
about the acceptability of lesser mediastinal sampling proce-
dures such as RS or no examination.
ACKNOWLEDGMENTS
Supported by a research grant from OSI Pharmaceu-
ticals (to R.U.O.).
The authors thank Matthew Smeltzer for statistics sup-
port and Mathew Ninan for clinical input.
REFERENCES
1. Rusch VW, Crowley J, Giroux DJ, et al; International Staging Commit-
tee; Cancer Research and Biostatistics; Observers to the Committee;
Participating Institutions. The IASLC Lung Cancer Staging Project:
proposals for the revision of the N descriptors in the forthcoming
seventh edition of the TNM classification for lung cancer. J Thorac
Oncol 2007;2:603–612.
2. Kramer H, Groen HJ. Current concepts in the mediastinal lymph node
staging of nonsmall cell lung cancer. Ann Surg 2003;238:180–188.
3. Detterbeck F, Puchalski J, Rubinowitz A, et al. Classification of the
thoroughness of mediastinal staging of lung cancer. Chest 2010;137:
436–442.
4. Zhong W, Yang X, Bai J, et al. Complete mediastinal lymphadenec-
tomy: the core component of the multidisciplinary therapy in resectable
non-small cell lung cancer. Eur J Cardiothorac Surg 2008;34:187–195.
5. Sugi K, Nawata K, Fujita N, et al. Systematic lymph node dissection for
clinically diagnosed peripheral non-small-cell lung cancer less than 2 cm
in diameter. World J Surg 1998;22:290–294.
6. Gajra A, Newman N, Gamble GP, et al. Effect of number of lymph
nodes sampled on outcome in patients with stage I non-small-cell lung
cancer. J Clin Oncol 2003;21:1029–1034.
7. Lardinois D, De Leyn P, Van Schil P, et al. ESTS guidelines for
intraoperative lymph node staging in non-small cell lung cancer. Eur
J Cardiothorac Surg 2006;30:787–792.
8. Scott WJ, Howington J, Feigenberg S, et al; American College of Chest
Physicians. Treatment of non-small cell lung cancer stage I and stage II:
ACCP evidence-based clinical practice guidelines (2nd edition). Chest
2007;132(3 Suppl):234S–242S.
9. Varlotto JM, Recht A, Nikolov M, et al. Extent of lymphadenectomy and
outcome for patients with stage I nonsmall cell lung cancer. Cancer
2009;115:851–858.
Journal of Thoracic Oncology • Volume 7, Number 2, February 2012 Objective Review of Mediastinal Lymph Node Examination
Copyright © 2012 by the International Association for the Study of Lung Cancer 395
10. Little AG, Rusch VW, Bonner JA, et al. Patterns of surgical care of lung
cancer patients. Ann Thorac Surg 2005;80:2051–2056.
11. Allen MS, Darling GE, Pechet TT, et al; ACOSOG Z0030 Study Group.
Morbidity and mortality of major pulmonary resections in patients with
early-stage lung cancer: initial results of the randomized, prospective
ACOSOG Z0030 trial. Ann Thorac Surg 2006;81:1013–1019.
12. Rami-Porta R, Wittekind C, Goldstraw P; International Association for
the Study of Lung Cancer (IASLC) Staging Committee. Complete
resection in lung cancer surgery: proposed definition. Lung Cancer
2005;49:25–33.
13. Osarogiagbon RU, Allen JW, Farooq A, et al. Outcome of surgical
resection for pathologic N0 and Nx non-small cell lung cancer. J Thorac
Oncol 2010;5:191–196.
14. Allen JW, Farooq A, O’Brien TF, et al. Quality of surgical resection for
nonsmall cell lung cancer in a US metropolitan area. Cancer 2011;117:
134–142.
15. RADIANT. Available at: http://www.clinicaltrials.gov/ct2/show/
NCT00373425?termRADIANT&rank4. Accessed April 21, 2011.
16. E1505 Trial Overview. Available at: http://www.ecog.dfci.harvard.edu/
general/E1505_trial_overview.pdf. Accessed April 21, 2011.
17. Kiyono K, Sone S, Sakai F, et al. The number and size of normal
mediastinal lymph nodes: a postmortem study. AJR Am J Roentgenol
1988;150:771–776.
18. Ricciardi R, Baxter NN. Association versus causation versus quality
improvement: setting benchmarks for lymph node evaluation in colon
cancer. J Natl Cancer Inst 2007;99:414–415.
19. Darling GE, Allen MS, Decker PA, et al. Number of lymph nodes
harvested from a mediastinal lymphadenectomy: results of the random-
ized, prospective American College of Surgeons Oncology Group Z0030
trial. Chest 2011;139:1124–29.
20. Izbicki JR, Passlick B, Pantel K, et al. Effectiveness of radical system-
atic mediastinal lymphadenectomy in patients with resectable non-small
cell lung cancer: results of a prospective randomized trial. Ann Surg
1998;227:138–144.
21. Wu Y, Huang ZF, Wang SY, et al. A randomized trial of systematic
nodal dissection in resectable non-small cell lung cancer. Lung Cancer
2002;36:1–6.
22. Stein JP, Penson DF, Cai J, et al. Radical cystectomy with extended
lymphadenectomy: evaluating separate package versus en bloc submis-
sion for node positive bladder cancer. J Urol 2007;177:876–881.
23. Fisher ER, Swamidoss S, Lee CH, et al. Detection and significance of
occult axillary node metastases in patients with invasive breast cancer.
Cancer 1978;42:2025–2031.
24. Crucitti F, Doglietto GB, Bellantone R, et al. Accurate specimen
preparation and examination is mandatory to detect lymph nodes and
avoid understaging in colorectal cancer. J Surg Oncol 1992;51:153–
157.
25. Darling GE, Allen MS, Decker PA, et al. Randomized trial of medias-
tinal lymph node sampling versus complete lymphadenectomy during
pulmonary resection in the patient with N0 or N1 (less than hilar)
non-small cell carcinoma: results of the American College of Surgery
Oncology Group Z0030 Trial. J Thorac Cardiovasc Surg 2011;141:662–
670.
26. Farjah F, Flum DR, Varghese TK Jr, et al. Surgeon specialty and
long-term survival after pulmonary resection for lung cancer. Ann
Thorac Surg 2009;87:995–1004.
27. Ou SH, Zell JA. Prognostic significance of the number of lymph nodes
removed at lobectomy in stage IA non-small cell lung cancer. J Thorac
Oncol 2008;3:880–886.
Osarogiagbon et al. Journal of Thoracic Oncology • Volume 7, Number 2, February 2012
Copyright © 2012 by the International Association for the Study of Lung Cancer396
